baricitinib

Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.

Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.

Baricitinib 4-aminobenzoic acid is a conjugate of a target protein ligand and a linker, incorporating a JAK2 ligand and a PROTAC linker that facilitates the recruitment of an E3 ligase. It is useful in the synthesis of the PROTAC JAK2 degrader, SJ1008030.

Baricitinib 4-aminobenzoic acid TFA is a derivative of Baricitinib 4-aminobenzoic acid and acts as a target protein ligand-linker conjugate. It includes a JAK2 ligand and a PROTAC linker capable of recruiting E3 ligase. This compound is useful in synthesizing the PROTAC JAK2 degrader SJ1008030.

Baricitinib-D3 is the deuterated form of Baricitinib. Baricitinib (T2485) (LY3009104; INCB028050) acts as a selective and orally administered inhibitor of JAK1 and JAK2, with IC50 values of 5.9 nM and 5.7 nM, respectively.

Baricitinib-D5 is a deuterated compound of Baricitinib. Baricitinib (T2485) has a CAS number of 1187594-09-7. Baricitinib (T2485) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.

Baricitinib-[D4] (Standard) is a reference standard of Baricitinib-[D4] intended for quantitative analysis, quality control, and related biochemical research applications.